Search Clinical Trials

7 Results

Not Yet Recruiting
Tolerability of Enteral NAC in Infants (External Link)
Biliary atresia (BA), a neonatal liver disease characterized by impaired bile flow, is the most common indication for pediatric liver transplantation. The only identified treatment option other than liver transplant …
Baylor Role: Collaborator
Acupuncture for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy (External Link)
The purpose is to find out if intraoperative acupuncture performed by needling PC 6 and LI4 point bilaterally, and Yin Tang point will help reduce the incidence postoperative nausea and …
Baylor Role: Lead Sponsor
N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy (External Link)
Biliary atresia (BA) is a disease characterized by fibro-obliteration of extrahepatic bile ducts leading to impaired bile flow (Sokol et al., 2007). BA is treated with the Kasai portoenterostomy (KP), …
Baylor Role: Lead Sponsor
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy (External Link)
ERCP with cholangioscopy is becoming a widespread technique to treat complicated choledocholithiasis, document CBD clearance after stone extraction and to assess biliary duct strictures. During the procedure, a large amount …
Baylor Role: Lead Sponsor
Pentoxifylline Therapy in Biliary Atresia (External Link)
Biliary atresia (BA) is a devastating liver disease of infancy of unknown etiology, characterized by bile duct obstruction, live fibrosis, and cirrhosis. BA has no known medical treatments. The only …
Baylor Role: Lead Sponsor
Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants (External Link)
Inpatient Use of Omegaven: Each family will have the severity of their child's condition explained to them and the available data regarding the benefit of the novel preparation explained using …
Baylor Role: Lead Sponsor
SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury (External Link)
Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - …
Baylor Role: Lead Sponsor